(19)
(11) EP 2 553 099 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
12.08.2015 Bulletin 2015/33

(45) Mention of the grant of the patent:
24.06.2015 Bulletin 2015/26

(21) Application number: 11761888.4

(22) Date of filing: 30.03.2011
(51) International Patent Classification (IPC): 
C12N 15/12(2006.01)
C12Q 1/68(2006.01)
 C07H 21/04(2006.01)
C07K 14/435(2006.01)
(86) International application number:
PCT/CA2011/050169
(87) International publication number:
WO 2011/120165 (06.10.2011 Gazette 2011/40)

(54)

MACROCYCLIC LACTONE RESISTANCE MARKER FOR DIROFILARIA IMMITIS

MARKER FÜR DIE RESISTENZ GEGEN MAKROZYKLISCHE LACTONE FÜR HERZWÜRMER

MARQUEUR DE RÉSISTANCE À LA LACTONE MACROCYCLIQUE POUR DIROFILARIA IMMITIS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 01.04.2010 US 319982 P

(43) Date of publication of application:
06.02.2013 Bulletin 2013/06

(73) Proprietors:
  • Novartis Tiergesundheit AG
    4058 Basel (CH)
  • The Royal Institution For The Advancement Of Learning/McGill University
    Montreal, Québec H3A 0G4 (CA)

(72) Inventors:
  • PRICHARD, Roger
    Ste-Anne-de-Bellevue, Québec H9X 3W6 (CA)
  • BOURGUINAT, Catherine
    Montreal, Québec H2X 2H7 (CA)
  • GEARY, Timothy
    Ste-Anne-de-Bellevue, Québec H9X 3L4 (CA)
  • SCHENKER, Rudolf
    CH-4002 Basel (CH)

(74) Representative: Spinner, David Richard 
Greaves Brewster LLP Copa House Station Road
Cheddar, Somerset BS27 3AH
Cheddar, Somerset BS27 3AH (GB)


(56) References cited: : 
EP-B1- 0 979 278
   
  • DATABASE EMBL [Online] 19 April 2007 (2007-04-19), "Wang-VSVGgfp-Jurkat-454-Avr-006514_1396_1 300 Wang-VSVGgfp-Jurkat-454-Avr Homo sapiens genomic, genomic survey sequence.", XP002708500, retrieved from EBI accession no. EM_GSS:EI523665 Database accession no. EI523665
  • PRICHARD ROGER K: "Ivermectin resistance and overview of the Consortium for Anthelmintic Resistance SNPs.", EXPERT OPINION ON DRUG DISCOVERY OCT 2007, vol. 2, no. s1, October 2007 (2007-10), pages S41-S52, XP009171670, ISSN: 1746-0441
  • CATHERINE BOURGUINAT ET AL: "Macrocyclic lactone resistance in Dirofilaria immitis", VETERINARY PARASITOLOGY, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 181, no. 2, 16 April 2011 (2011-04-16), pages 388-392, XP028286326, ISSN: 0304-4017, DOI: 10.1016/J.VETPAR.2011.04.012 [retrieved on 2011-04-16]
  • JEFFREY N. CLARK: "Comment on the paper "Macrocyclic lactone resistance in Dirofilaria immitis" by Bourguinat et al.", VETERINARY PARASITOLOGY, vol. 182, no. 2-4, 15 June 2011 (2011-06-15), pages 378-379, XP055073832, ISSN: 0304-4017, DOI: 10.1016/j.vetpar.2011.06.009
  • TIMOTHY G GEARY ET AL: "Evidence for Macrocyclic Lactone Anthelmintic Resistance in", TOPICS IN COMPANION ANIMAL MEDICINE, vol. 26, no. 4, November 2011 (2011-11), pages 186-192, XP028337100, ISSN: 1938-9736, DOI: 10.1053/J.TCAM.2011.09.004 [retrieved on 2011-10-08]
  • BOURGUINAT, C. ET AL.: 'P-glycoprotein-like protein, a possible genetic marker for invermectin resistance selection in Onchocerca volvulus.' MOL. BIOCHEM. PARASITOL. vol. 158, 2008, pages 101 - 111, XP022485730
  • MEALEY, K. L.: 'Canine ABCB1 and macrocyclic lactones: Heartworm prevention and pharmacogenetics.' VET. PARASITOL. vol. 158, 2008, pages 215 - 222, XP025633063
  • BOURGUINAT, C. ET AL.: 'Correlation between loss of efficacy of macrocyclic lactone heartworm anthemlintics and P-glycoprotein genotype.' VET. PARASITOL. vol. 176, 22 March 2011, pages 374 - 381, XP028156255
  • BOURGUINAT, C. ET AL.: 'Genetic polymorphism in Dirofilaria immitus.' VET. PARASITOL. vol. 176, 22 March 2011, pages 368 - 373, XP028156254
  • DATABASE GENBANK 11 March 2011 BOURGUINAT, C. ET AL., XP008161229 Database accession no. HM596853
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).